INCY - Incyte Non-GAAP EPS of $1.10 beats by $0.04 revenue of $919M misses by $44.09M
2023-10-31 07:01:29 ET
More on Incyte
- Incyte: One Of The Most Undervalued Pharmaceuticals
- Incyte Q2: Revenue Growth Offset By Rising Operational Costs
- Incyte Q3 2023 Earnings Preview
- Incyte says study evaluating efficacy of ruxolitinib cream in children met primary endpoint
- Seeking Alpha’s Quant Rating on Incyte
For further details see:
Incyte Non-GAAP EPS of $1.10 beats by $0.04, revenue of $919M misses by $44.09M